GOTHENBURG, Sweden, June 13, 2026
MGI Tech Co., Ltd. (MGI) unveiled major initiatives to strengthen the global genomics ecosystem at the European Society of Human Genetics (ESHG) 2026 Conference, highlighting new collaborations in clinical genomics, next-generation sequencing (NGS), laboratory automation, and precision medicine. The company showcased an expanded portfolio of sequencing and automation technologies while launching its new NGS Partner Enablement Program and announcing expanded OEM collaboration opportunities designed to accelerate the adoption of regulated genomic testing worldwide. The developments underscore MGI’s commitment to advancing clinical diagnostics and enabling broader access to precision healthcare through integrated genomics solutions. As genomic technologies continue to transform disease diagnosis and personalized treatment strategies, MGI is positioning itself as a key technology partner for laboratories, researchers, healthcare providers, and diagnostics developers across Europe and beyond.
MGI Launches NGS Partner Enablement Program for Clinical Genomics
One of the most significant announcements at ESHG 2026 was the launch of the MGI NGS Partner Enablement Program, a strategic initiative designed to connect diagnostic developers, assay providers, software companies, automation specialists, and clinical laboratories operating within the genomic testing landscape. The program aims to simplify the development and implementation of validated clinical workflows on MGI sequencing platforms while accelerating the deployment of regulated next-generation sequencing applications. By fostering collaboration across the genomics value chain, MGI seeks to reduce development timelines, improve workflow standardization, and increase access to high-quality genomic testing.
The initiative reflects growing demand for integrated solutions that support the expansion of precision medicine, oncology diagnostics, inherited disease testing, pharmacogenomics, and population genomics programs. Through these partnerships, MGI aims to help laboratories transition more efficiently from research applications to clinical implementation while supporting regulatory compliance and operational scalability.
New OEM Collaborations Expand Laboratory Automation Solutions
Advertisement
MGI also announced new opportunities for Original Equipment Manufacturer (OEM) collaborations built around its integrated sequencing and library preparation platforms. The company highlighted its DE Bundle portfolio, including the current D4+E25 platform and the newly introduced D16 and E25 system combination, which incorporates a new 50M flow cell designed to increase throughput and laboratory efficiency. Scheduled for launch later this year, the D16 serves as the next-generation successor to the D4 and features advanced robotic pipetting technology, fully enclosed contamination control, and expanded sample processing capabilities.
The platform is designed to automate complex laboratory workflows and provide flexible solutions for genomic testing laboratories. Through its open OEM ecosystem, MGI enables partners to integrate automation technologies into customized workflows tailored to specific research and clinical applications. The strategy supports improved laboratory productivity, workflow standardization, and scalable genomic testing infrastructure as demand for sequencing continues to increase globally.
Precision Medicine and Multi-Omics Research Drive Innovation
During its Corporate Satellite Symposium, MGI brought together leading European researchers to demonstrate how advanced genomic technologies are delivering real-world impact in precision oncology, pharmacogenomics, and spatial multi-omics research. Presentations highlighted the use of RNA sequencing for identifying actionable gene fusions in solid tumors, spatial biology technologies for mapping tumor microenvironments in melanoma, and whole genome sequencing approaches for evaluating pharmacogenetic markers that support personalized treatment decisions. These examples demonstrated how genomic technologies are enabling clinicians and researchers to generate actionable insights that improve disease diagnosis, patient stratification, and therapeutic decision-making.
MGI also showcased its high-throughput T7+ sequencing platform, which continues to gain adoption across research and clinical laboratories worldwide. By combining advanced sequencing systems, automation technologies, and collaborative partnerships, MGI is helping accelerate the integration of genomics into routine healthcare. The company believes these efforts will play a crucial role in advancing precision medicine, translational research, and data-driven healthcare, supporting the next generation of genomic innovation across Europe and global markets.
Source: MGI Tech press release
